Raymond James upgraded ARS Pharmaceuticals to Strong Buy from Outperform with a price target of $22, up from $18.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRY:
- Aquestive Therapeutics price target raised to $15 from $13 at Oppenheimer
- ARS Pharmaceuticals Receives FDA Approval of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
- ARS Pharmaceuticals receives FDA approval of neffy
- ARS Pharmaceuticals to Participate in the 2024 Wedbush PacGrow Healthcare Conference
- ARS Pharmaceuticals reports Q2 EPS (13c), consensus (12c)
Questions or Comments about the article? Write to editor@tipranks.com